GI Innovation Inc banner
G

GI Innovation Inc
KOSDAQ:358570

Watchlist Manager
GI Innovation Inc
KOSDAQ:358570
Watchlist
Price: 12 170 KRW -2.87% Market Closed
Market Cap: ₩780B

Multiples-Based Value

The Multiples-Based Value of one GI Innovation Inc stock under the Base Case scenario is 104.2 KRW. Compared to the current market price of 12 170 KRW, GI Innovation Inc is Overvalued by 99%.

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Multiples-Based Value
Base Case
104.2 KRW
Overvaluation 99%
Multiples-Based Value
Price ₩12 170
G
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
GI Innovation Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
GI Innovation Inc
KOSDAQ:358570
774.8B KRW 2 291.7 -14.9 -17.4 -16.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
365.4B USD 6 87.3 14.5 20.1
US
Amgen Inc
NASDAQ:AMGN
184.6B USD 5 23.9 13.9 13.9
US
Gilead Sciences Inc
NASDAQ:GILD
173.9B USD 5.9 20.5 12.8 15.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
110.3B USD 9.2 27.9 20.9 21.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.7B USD 5.6 17.9 13.4 15.2
AU
CSL Ltd
ASX:CSL
67B AUD 3 33.2 11.2 14
NL
argenx SE
XBRU:ARGX
39.6B EUR 11.3 36.2 39.3 40.1
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
P/S Multiple
Revenue Growth P/S to Growth
KR
G
GI Innovation Inc
KOSDAQ:358570
Average P/S: 3 063 211.1
2 291.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5
3%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
5.9
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.2
11%
0.8
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
10%
0.6
AU
CSL Ltd
ASX:CSL
3
4%
0.8
NL
argenx SE
XBRU:ARGX
11.3
28%
0.4
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
KR
G
GI Innovation Inc
KOSDAQ:358570
Average P/E: 35.3
Negative Multiple: -14.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
87.3
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
23.9
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
20.5
16%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.9
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
13%
1.4
AU
CSL Ltd
ASX:CSL
33.2
10%
3.3
NL
argenx SE
XBRU:ARGX
36.2
32%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
G
GI Innovation Inc
KOSDAQ:358570
Average EV/EBITDA: 18
Negative Multiple: -17.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.5
12%
1.2
US
Amgen Inc
NASDAQ:AMGN
13.9
10%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
9%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.9
16%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.4
18%
0.7
AU
CSL Ltd
ASX:CSL
11.2
7%
1.6
NL
argenx SE
XBRU:ARGX
39.3
50%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
G
GI Innovation Inc
KOSDAQ:358570
Average EV/EBIT: 20.2
Negative Multiple: -16.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
20.1
23%
0.9
US
Amgen Inc
NASDAQ:AMGN
13.9
3%
4.6
US
Gilead Sciences Inc
NASDAQ:GILD
15.8
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.9
17%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.2
23%
0.7
AU
CSL Ltd
ASX:CSL
14
10%
1.4
NL
argenx SE
XBRU:ARGX
40.1
51%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett